Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Absci Corp (ABSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ABSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.3% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 305.60M USD | Price to earnings Ratio - | 1Y Target Price 8.62 |
Price to earnings Ratio - | 1Y Target Price 8.62 | ||
Volume (30-day avg) 4126068 | Beta 2.1 | 52 Weeks Range 2.30 - 6.72 | Updated Date 04/2/2025 |
52 Weeks Range 2.30 - 6.72 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate -0.2238 | Actual -0.25 |
Profitability
Profit Margin - | Operating Margin (TTM) -4266.77% |
Management Effectiveness
Return on Assets (TTM) -31.18% | Return on Equity (TTM) -58.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 203281328 | Price to Sales(TTM) 67.4 |
Enterprise Value 203281328 | Price to Sales(TTM) 67.4 | ||
Enterprise Value to Revenue 44.83 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 127334000 | Shares Floating 100727471 |
Shares Outstanding 127334000 | Shares Floating 100727471 | ||
Percent Insiders 15.17 | Percent Institutions 58.42 |
Analyst Ratings
Rating 4.44 | Target Price 8.25 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Absci Corp
Company Overview
History and Background
Absci Corp. was founded in 2011. It focuses on developing AI-powered drug creation platform for biopharmaceutical discovery and development. It went public in July 2021. Key milestones include platform validation through partnerships and advancements in integrated drug creation.
Core Business Areas
- Integrated Drug Creation Platform: Absci's core business is its AI-powered Integrated Drug Creation Platform. This platform enables the design and discovery of novel biotherapeutics.
- Drug Discovery Partnerships: Absci partners with pharmaceutical and biotechnology companies to discover and develop new drug candidates using its platform.
Leadership and Structure
Sean McClain is the CEO of Absci Corp. The company has a board of directors with expertise in biotechnology and pharmaceuticals. The organizational structure includes research and development, platform engineering, and business development teams.
Top Products and Market Share
Key Offerings
- Integrated Drug Creation Platform: Absci's Integrated Drug Creation Platform is its primary offering, providing end-to-end drug discovery capabilities. While precise market share data is unavailable, competition includes companies offering various stages of biopharmaceutical R&D support. Competitors include companies like Schru00f6dinger, Recursion Pharmaceuticals, and other AI-driven drug discovery platforms.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing a growing adoption of AI and machine learning to accelerate drug discovery and development. There is a strong demand for innovative technologies that can improve the efficiency and success rates of drug development processes.
Positioning
Absci is positioned as an innovator in AI-powered drug discovery. Its competitive advantages include its integrated platform and partnerships with established pharmaceutical companies.
Total Addressable Market (TAM)
The TAM for AI in drug discovery is estimated to reach billions of dollars. Absci is positioned to capture a portion of this market through its partnerships and platform capabilities.
Upturn SWOT Analysis
Strengths
- AI-powered drug creation platform
- Integrated end-to-end capabilities
- Partnerships with major pharmaceutical companies
- Strong IP portfolio
Weaknesses
- Relatively young company
- High R&D expenses
- Dependence on partnerships for revenue
- Still evolving platform
Opportunities
- Expanding partnerships with pharmaceutical companies
- Developing new applications for the platform
- Increasing adoption of AI in drug discovery
- Potential for platform licensing
Threats
- Competition from other AI-driven drug discovery companies
- Regulatory hurdles for new drug development
- Failure of drug candidates in clinical trials
- Economic downturn affecting R&D spending
Competitors and Market Share
Key Competitors
- Schru00f6dinger (SDGR)
- Recursion Pharmaceuticals (RXRX)
- Relay Therapeutics (RLAY)
Competitive Landscape
Absci's advantages include its integrated platform. Disadvantages could include its smaller size compared to some established competitors and ongoing need for capital to fuel growth.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Absci's historical growth depends on revenue and partnership data available in past annual reports.
Future Projections: Future growth projections come from analyst estimates, typically available from financial news sources.
Recent Initiatives: Recent initiatives include partnership announcements, platform updates, and strategic investments.
Summary
Absci Corp is a relatively young company focusing on AI-powered drug creation. Its integrated platform and partnerships show promise, but it faces competition and requires significant R&D investment. The company's success hinges on the performance of its platform and its ability to secure and expand partnerships. Market acceptance of AI in drug discovery is a critical factor for its growth, as is the success rate of its drug candidates.
Similar Companies
RLAY
Relay Therapeutics Inc
RLAY
Relay Therapeutics Inc
RXRX
Recursion Pharmaceuticals Inc
RXRX
Recursion Pharmaceuticals Inc
SDGR
Schrodinger Inc
SDGR
Schrodinger Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Absci Corp
Exchange NASDAQ | Headquaters Vancouver, WA, United States | ||
IPO Launch date 2021-07-22 | Founder, CEO, President & Director Mr. Sean McClain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 156 | Website https://www.absci.com |
Full time employees 156 | Website https://www.absci.com | ||
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its integrated drug creation platform comprises AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets, as well as improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.